Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study concluded that androgenetic alopecia was not a prognostic indicator for COVID-19, but hospitalization frequency increased in older patients with benign prostatic hyperplasia, supporting an androgen-mediated severity hypothesis.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

This study found that the risk of urinary stone disease increased significantly in patients with severe androgenetic alopecia, and that testosterone deficiency was more frequent among these patients.

This study found that nonobese women with idiopathic hirsutism had significantly lower nitrite/nitrate concentrations and higher fibrinogen levels compared to controls, but similar levels to women with PCOS.

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Hair loss can be an early sign of prostate enlargement.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This study reports that new compounds with anti-androgenic effects were found to counteract testosterone in animals without significant estrogenic activity, indicating potential for managing androgen-related conditions.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

This review describes the clinical features of testosterone deficiency syndrome in aging men but reports no new experimental findings, highlighting the need for clinical recognition and treatment of TDS.